University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Biochemistry & Molecular
Biology

Biochemistry & Molecular Biology

6-10-2011

TNFα
TNF enhances the motility and invasiveness of prostatic cancer
cells by stimulating the expression of selective glycosyl- and
sulfotransferase genes involved in the synthesis of selectin
ligands.
Prakash Radhakrishnan
University of Nebraska Medical Center, pradhakr@unmc.edu

Vishwanath Chachadi
University of Nebraska Medical Center

Ming-Fong Lin
University of Nebraska Medical Center, mlin@unmc.edu

Rakesh Singh
University of Nebraska Medical Center, rsingh@unmc.edu

Reiji Kannagi
Aichi Cancer Center
Follow this and additional works at: https://digitalcommons.unmc.edu/com_bio_articles
Part of the Medical Biochemistry Commons, and the Medical Molecular Biology Commons
See next page for additional authors

Recommended Citation
Radhakrishnan, Prakash; Chachadi, Vishwanath; Lin, Ming-Fong; Singh, Rakesh; Kannagi, Reiji; and Cheng,
Pi-Wan, "TNFα enhances the motility and invasiveness of prostatic cancer cells by stimulating the
expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of selectin ligands."
(2011). Journal Articles: Biochemistry & Molecular Biology. 42.
https://digitalcommons.unmc.edu/com_bio_articles/42

This Article is brought to you for free and open access by the Biochemistry & Molecular Biology at
DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Biochemistry & Molecular Biology
by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

Authors
Prakash Radhakrishnan, Vishwanath Chachadi, Ming-Fong Lin, Rakesh Singh, Reiji Kannagi, and Pi-Wan
Cheng

This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_bio_articles/42

NIH Public Access
Author Manuscript
Biochem Biophys Res Commun. Author manuscript; available in PMC 2014 May 06.

NIH-PA Author Manuscript

Published in final edited form as:
Biochem Biophys Res Commun. 2011 June 10; 409(3): 436–441. doi:10.1016/j.bbrc.2011.05.019.

TNFͣ enhances the motility and invasiveness of prostatic
cancer cells by stimulating the expression of selective glycosyland sulfotransferase genes involved in the synthesis of selectin
ligands
Prakash Radhakrishnana, Vishwanath Chachadia, Ming-Fong Lina,b, Rakesh Singhb,c, Ajit
Varkid, Reiji Kannagie, and Pi-Wan Chenga,b,*
aDepartment

of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska
Medical Center, Omaha, NE 68198

bEppley

NIH-PA Author Manuscript

Cancer Center for Research in Cancer and Allied diseases, University of Nebraska
Medical Center, Omaha, NE 68198
cDepartment

of Pathology and Microbiology University of Nebraska Medical Center, Omaha, NE

68198
dUniversity
eAichi

of California at San Diego, San Diego, CA

Cancer Center, Nagoya, Japan

Abstract
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Sialyl Lewis X (sLex) plays an important role in cancer metastasis. But, the mechanism for its
production in metastatic cancers remains unclear. The objective of current study was to examine
the effects of a pro-inflammatory cytokine on the expression of glycosyltransferase and
sulfotransferase genes involved in the synthesis of selectin ligands in a prostate cancer cell line.
Androgen-independent human lymph node-derived metastatic prostate cancer cells (C-81
LNCaP), which express functional androgen receptor and mimic the castration-resistant advanced
prostate cancer, was used. TNFͣ treatment of these cells increased their binding to P-, E- and Lselectins, anti-sLex antibody, and anti-6-sulfo-sialyl Lewis x antibody by 12, 240, 43, 248 and
21%, respectively. Also, the expression of C2GnT-1, B4GalT1, GlcNAc6ST3, and ST3Gal3 genes
was significantly upregulated. Further treatment of TNFͣ-treated cells with either anti-sLex
antibody or E-selectin significantly suppressed their in vitro migration (81 and 52%, respectively)
and invasion (45 and 56%, respectively). Our data indicate that TNFͣ treatment enhances the
motility and invasion properties of LNCaP C-81 cells by increasing the formation of selectin
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ligands through stimulation of the expression of selective glycosyl- and sulfotransferase genes.
These results support the hypothesis that inflammation contributes to cancer metastasis.
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1. Introduction
Prostate cancer is the second leading cause of cancer death of men in the United States [1].
At the time of initial diagnosis, more than 70% of prostate cancer patients have lymph node
metastases [2–5]. Although metastasis is the primary cause of the fatalities of cancer
patients, the mechanism is not completely understood. One key step in the cancer metastatic
process is the adhesion of circulating cancer cells to the endothelium at distant sites. This
step involves selectin-ligand interactions between host cells (selectins) and cancer cells
(selectin ligands). Understanding how the production of these two key players is regulated
during cancer progression could help develop cancer therapeutic strategy.
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Selectins are a family of type II transmembrane proteins found on the surface of leukocytes,
platelets and activated endothelial cells. They are calcium-dependent C-type lectins [6]. The
three major types of selectins include E-, P-, and L-selectins, which are located on
endothelium, platelets and activated endothelium, and leukocytes, respectively [6]. The
naturally occurring vascular carbohydrate ligands for these selectins include E-selectin
ligand-1 (ESL-1), P-selectin glycoprotein ligand-1 (PSGL-1), CD34, cutaneous lymphocyteassociated antigen (CLA), glycoprotein GlyCAM-1, MAdCAM-1, Podocalyxin-like protein
and Sgp200 [7]. These selectin-ligand interactions were originally shown to be involved in
the trafficking of immune cells to inflamed tissues [8] and lymphoid organs, and recently in
the metastasis of cancer cells [9]. The naturally occurring vascular ligands for these selectin
molecules are mostly mucin-type glycoproteins which carry sialylated, fucosylated and
sulfated glycans [10] although some N-linked glycans also can participate in this process
[11]. Increased expression and altered glycosylation of mucins are prominent features of
carcinoma progression [10]. For example, sialyl Lewis x (sLex) and sialyl lewis a (sLea) are
increased substantially in tumors [12], including prostate cancers [13, 14]. Elevated
expression of sLex and sLea on mucin type O-glycans is highly correlated with lymphatic
and venous invasion of cancerous cells [15, 16]. SLex and 6-sulfo-sLex also were elevated
under in vivo inflammatory condition [9] and in vitro induction with proinflammatroy
cytokine, tumor necrosis factor ͣ(TNFͣ) [17, 18]. Glycosyland sulfotransferases
responsible for the biosynthesis of the above mentioned epitopes were selectively
upregulated in various cancers [19] and inflammatory conditions [9] and/or cells treated
with TNFͣ[17, 18]. However, a concerted effort to correlate the effects of inflammatory
cytokine on the expression of selectin ligands, glycosyl- and sulfotransferase genes
responsible for the synthesis of these ligands, interactions of these ligands with selectins,
and the acquisition of metastatic potential of the TNFͣ-treated cells was lacking.

Biochem Biophys Res Commun. Author manuscript; available in PMC 2014 May 06.

Radhakrishnan et al.

Page 3

NIH-PA Author Manuscript

Recently, serum TNFͣ level was found to be increased in prostate cancer patients with
metastatic disease and elevated PSA [20]. This observation prompted us to examine whether
TNFͣ could enhance the metastatic potential of prostate cancer cells via stimulating the
production of sLex, an important determinant of cancer metastasis. To carry out a more
comprehensive study on the effect of TNFͣ on the acquisition of the sLex-related metastatic
potential in prostate cancer, we employed LNCaP C-81 cells, which exhibit properties
mimicking the clinical characteristics of advanced prostate cancers [21–23]. C-81 cells are
androgen independent, grow faster and have high colony-forming property on soft agar as
compared to LNCaP parental C-33 cells [22]. We found that treatment of the C-81 LNCaP
cells with TNFͣ increased the motility and invasiveness, which accompanied an increase in
selectin ligands resulted from elevated expression of selected glycosyl- and sulfotransferase
genes.

3. Materials and methods
2.1 Cell lines
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The human Prostate cancer cell line LNCaP was originally purchased from the American
Type Culture Collection ATCC (Rockville, MD). The LNCaP cell model including C-33
and C-81 cells used in the present study was developed by Lin et al [22] and further
characterized by Igawa et al [21]. The cell line was maintained in RPMI 1640 medium
supplemented with 5% Fetal bovine serum, 1% L-glutamine and 1% PenicillinStreptomycin.
2.2 Flow Cytometry analysis of selectin interactions with ligands on LNCaP cells
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Flow cytometry analysis of selectin-ligand interaction on cancer cells was carried out as
described previously [24]. Briefly, LNCaP cells of both control and TNFͣ(20 ng/ml, 36 h)
treated were detached from plates after incubation with PBS containing 2 mM EDTA for 5
min at 37 °C, washed three times with Hanks’ balanced salt solution (HBSS), and then
treated with 0.5% BSA in HBSS for 30 min to block nonspecific binding. Chimeras of
selectins P (50 µg/ml), E (50 µg/ml), and L (50 µg/ml) fused with Fc region of human IgG
were purified from human 293 cells (transformed embryonic kidney fibroblast cell line) of
Psel IgG, ESIg B3293 and LSRg293 Cytel, respectively [24]. These selectins were preincubated with a goat-anti human IgG conjugated with FITC for 1 h at room temperature.
Similarly, sLex (KM93) (10 µg/ml) and 6-sulfo-sLex (G152) (1:10 diluted) [25] mouse
monoclonal antibodies were pre-incubated with goat anti-mouse antibody conjugated with
FITC before use. These complexes (Selectin, KM93 Ab, or G152 Ab complexed with
respective FITC-conjugated secondary antibodies) were incubated with tumor cells at 4 °C
for 2 h and then washed successively with HBSS/BSA and HBSS. Then cells were fixed
with 2 % (wt/vol) paraformaldehyde in HBSS at room temperature for 15–30 min. The cells
were then washed with HBSS and resuspended in 1 ml of HBSS/BSA for flow cytometry
analysis. Controls were cells stained in a presence of 5 mM EDTA (calcium chelation) or 30
mM EDTA in the case of P-selectin. In some instances, tumor cell surfaces were pretreated
before probing for selectin ligands. Cells treated with FITC-conjugated secondary antibody
alone served as an antibody control.
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2.3 Real Time PCR analysis of the expression of glycosyl- and sulfotransferase genes
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RT-PCR analyses on LNCaP C-81 cells were performed as described previously [26]. Total
cellular RNAs were isolated from TNFͣ treated (20 ng/ml, 3 h) and control LNCaP cells
using the TRI-REAGENT (Molecular Research Center, Inc, USA) according to the
manufacturer protocol. cDNA was synthesized by using 2 µg of total RNA as the template in
a 20 µl RT reaction mixture by using Verso™ cDNA kit (ABgene, UK) according to the
manufacturer instruction. Quantitative real time PCR was performed on a Master cycler ep
realplex2 (Eppendorf AG, Hamburg) using SYBR Green PCR kit (Takara Bio Inc, USA).
The forward and reverse primers used for amplification of selective glycosyl- and
sulfotransferase genes are listed in Table 1. The data were analyzed using Eppendorf
realplex software, version 1.5 (Eppendorf). The amounts of various glycogene transcripts
were normalized to the amount of GAPDH transcript in same cDNA sample and expressed
as % of GAPDH. Relative fold differences in transcript expression were determined using
the following comparative CT method: 2−[ Ct(TNFͣ)- Ct(Control)]=2− Ct, where
Ct=Ct(Target)-Ct(GAPDH) as described previously [26]. The results were expressed as the
amount (%) relative to that (100 %) of GAPDH and plotted as mean fold changes ± SEM.
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2.4 Motility and Invasion assays
Motility and invasion assays were performed as previously described [23]. For motility
assays, 5×104 cells/ml of control, TNFͣ treated (20 ng/ml, 36 h), and TNFͣ treated cells
further incubated with sLex monoclonal antibody KM93 (10 µg/ml) or E-selectin (100
µg/ml) were placed on the top chamber of non-coated polyethylene terapthalate membranes.
After incubation for 24 h, the cells that did not migrate through the pores in the membrane
were removed by scraping the membrane with a cotton swab. Cells that transversed the
membranes were stained with a Diff-Quick cell staining kit (Dade Behring, Inc., Newark,
DE). Invasion assay of prostate cancer cells was carried out as described above except that
24 well BD BioCoat™ Matrigel™ invasion chambers (8 µm pore size; Becton Dickinson)
were used and the incubation time was 22 h. Cells at three random fields per insert were
counted with 40× magnification and expressed as the average number of cells per field of
view. Three independent experiments were performed in triplicates in each condition. The
data were presented as the mean of three independent experiments ±SD.
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3.5 Statistical Analysis
The Student’s t-test was used for analysis of the significance of differences in means
between control and tested samples. P<0.05 was considered significant.

4. Results
3.1 TNFͣ enhancement of selectin binding to LNCaP cells
LNCaP C-81 cells with and without TNFͣ treatment were assessed for their binding to P-,
E-, and L-selectins by flow cytometry. These cells exhibited a decreasing order of selectin
binding, P-selectin > L-selectin > E-selectin, in the untreated controls (Figs. 1A–C). TNFͣ
treatment increased the number of cells that bind to E, P, and L-selectins by 240%
(p<0.001), 12% (p<0.05), and 43% (p<0.05), respectively (Fig. 1A–C).
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3.2 TNFͣ enhancement of sLex and 6-sulfo-sLex epitopes on LNCaP cells
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The E- and L-selectin ligands, sLex and 6-sulfo-sLex, on C-81 LNCaP cells were assessed
with KM93 and G152 antibodies, respectively. As shown in Fig. 2A and 2B, TNFͣ
treatment increased the binding of LNCaP cells to KM93 and G152 antibodies by 248%
(p<0.001) and 21% (p<0.05), respectively.
3.3 TNFͣ modulation of the expression of glycosyl- and sulfotransferase genes involved in
the synthesis of selectin ligands
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The TNFͣ-induced changes in the expression of the glycosyl- and sulfotransferase genes
involved in the synthesis of mucin-type selectin ligands were assessed by real time PCR
analysis. As shown in Fig. 3, TNFͣ treatment of LNCaP cells significantly increased the
expression of the following genes (% increase over the control): C2GnT1 (340%) (p<0.01),
B4GalT1 (68%) (p<0.05), GlcNAc6ST3 (760%) (p<0.01) and ST3Gal3 (240%) (p<0.05).
Although C1GALT1 gene expression was not affected by TNFͣ, it did express at a high
basal level, i.e. 0.11% of GAPDH. However, the gene expression level of core 1 extension
enzyme, B3GnT3, was very low, i.e. 0.00006% of GAPDH. C2GnT1 is the highest expresser
among the three C2GnT isozymes. All B4GalTs were expressed at very high levels. After
TNFͣ treatment, GlcNAc6ST1 & 3 were expressed at modest levels, ST3Gal4 was the
highest expresser among the three ST3Gal isozymes and FUT4 was the highest expresser
among the FUT genes.
3.4 TNFͣ enhancement of in vitro motility and invasion of LNCaP cells
The motility and invasion properties of LNCaP cells treated with TNFͣ were analyzed by in
vitro Boyden chamber assay. As shown in Fig. 4A–4C, TNFͣ treatment significantly
increased the number of cells that migrated through polyethylene terapthalate membrane by
83% (p<0.001) and those that invaded the matrigel by 44% (p<0.001) when compared with
the untreated cells. Incubation of the TNFͣ–treated cells with KM93 antibodies and Eselectin reduced the number of cells that migrated through polyethylene terapthalate
membrane by 81% (p<0.001) and 52% (p<0.001), respectively, and those that invaded the
matrigel by 45% (p<0.001) and 56% (p<0.001), respectively when compared with the cells
treated with TNFͣ only.
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4. Discussion
Metastasis is the primary cause of cancer death. and inflammation is a key contributor of
cancer metastasis [27, 28]. Current study shows that TNFͣ, a proinflammatory cytokine,
enhances the motility and invasiveness of human prostate cancer cells by stimulating the
expression of selective glycosyl- and sulfotransferase genes involved in the synthesis of
selectin ligands. These results support the role of inflammation in cancer metastasis [29].
Cancer metastasis involves several highly coordinated steps, including escaping of tumor
cells from the primary sites, transport of these cells by circulation to the lymphoid organs
and/or distant sites, adhesion of these cells to the inflamed endothelium at these sites, and
then establishment of tumors. Interactions of selectins and their ligands play a crucial role in
the second and third steps of the metastatic process as described above. The circulating
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metastatic cancer cells provide sLex, an E-selectin ligand, to facilitate their arrest by the Eselectin present on the activated endothelium at distant sites [30,31]. The L-selectin ligand,
6-sulfo-sLex, expressed on the surface of these cancer cells help them adhere to the
circulating leukocytes by binding to L-selectin expressed on the surface of leukocytes,
which facilitates their transport to the lymphoid organs and inflamed endothelium at distant
sites. The P-selectin ligand expressed on these cancer cells render these cells capable of
adhering to P-selectin present on the activated endothelium at distant sites and on circulating
platelets, which help these cancer cells to metastasize [30]. The increased expression of P-,
E-, and L-selectin ligands on these cancer cells following treatment with TNFͣ could
enhance the potential of these cells to target to the lymphoid organs and inflamed
endothelium at distant sites. In this study, we have shown that TNFͣ enhances the motility
and invasiveness of these prostate cancer cells. Confirmation of this observation in vivo
remains to be made.
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SLex and 6-sulfo-sLex can be found on core 1 and core 2 mucin glycans [31,32]. The
formation of these glycotopes is controlled by the levels of these enzymes of which
expression is subject to regulation [31,33]. For example, TNFͣ has been shown to increase
the production of sialylated and/or sulfated Lewis x epitopes in the human bronchial mucosa
by stimulating the expression of glycosyl- and sulfotransferases responsible for their
synthesis [18]. The enzymes responsible for the enhancement of these glycotopes have been
shown to be FUT3 & 4, ST3Gal3 & 4, and GlcNAc6STs. TNFͣ also can enhance the
production of sulfated N-acetyllactosamine, a precursor of 6-sulfo-sLex on CD44 of a SR91
myloid cell line [34]. In this report, we showed increased production of P-, E-, and Lselectin ligands on LNCaP cells treated with TNFͣ. Upregulation of C2GnT-1, B4GalT1,
GlcNAc6ST3 and ST3Gal3 genes coupled with high expression levels of additional glycosyland sulfotransferase genes can explain the formation of these selectin ligands in response to
TNFͣ treatment. However, the low expression level (0.00005% of GAPDH) of the core 1
extension enzyme (B3GnT3) suggests that the core 1 can not be extended to support the
formation of these glycotopes on this core structure. Therefore, these selectin ligands are
most likely localized to the core 2 branch. This prediction remains to be confirmed by
glycan analysis.
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We extended the biochemical and molecular biological observations by showing that TNFͣinduced changes in glycogene expression profile led to increased binding of these cells to P-,
E-, and L-selectins, and increased their adhesion, motility, and invasion properties. This
observation confirmed a previous report that TNFͣ increased migration and invasion of a
human melanoma cell line [35]. Collectively, these results support the idea that
inflammatory cytokines can enhance the metastatic properties of cancer cells and further
substantiate the link between inflammation and cancer progression as previously described
[27, 28].
In conclusion, the present study shows the TNFͣ effect on enhancement of prostate cancer
cell migration and invasion through activation of selective glycosyl and sulfotransferase
genes involved in the biosynthesis of sialylated and/or sulfated sLex. These genes may serve
potential therapeutic targets.

Biochem Biophys Res Commun. Author manuscript; available in PMC 2014 May 06.

Radhakrishnan et al.

Page 7

Acknowledgments
NIH-PA Author Manuscript

We wish to acknowledge the research support from NIH RO1 CA88184 (MFL), RO1 HL48282 and R21 HL97238,
the State of Nebraska-NRI cancer glycobiology program and LB506 (PWC), and the Department of Defense
Postdoctoral Fellowship (PR), and expert technical assistance of Helen Cheng.

References

NIH-PA Author Manuscript
NIH-PA Author Manuscript

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer. J. Clin. 2010; 60:277–300.
[PubMed: 20610543]
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N. Engl. J. Med. 2003; 349:366–381.
[PubMed: 12878745]
3. Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited:
Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis.
Proc. Natl. Acad. Sci. U. S. A. 2001; 98:3352–3357. [PubMed: 11248082]
4. Imai Y, Singer MS, Fennie C, Lasky LA, Rosen SD. Identification of a carbohydrate-based
endothelial ligand for a lymphocyte homing receptor. J. Cell Biol. 1991; 113:1213–1221. [PubMed:
2040648]
5. Hemmerich S, Butcher EC, Rosen SD. Sulfation-dependent recognition of high endothelial venules
(HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. J. Exp.
Med. 1994; 180:2219–2226. [PubMed: 7525849]
6. Varki A. Selectin ligands. Proc. Natl. Acad. Sci. U. S. A. 1994; 91:7390–7397. [PubMed: 7519775]
7. Yeh JC, Hiraoka N, Petryniak B, Nakayama J, Ellies LG, Rabuka D, Hindsgaul O, Marth JD, Lowe
JB, Fukuda M. Novel sulfated lymphocyte homing receptors and their control by a Core1 extension
beta 1,3-N-acetylglucosaminyltransferase. Cell. 2001; 105:957–969. [PubMed: 11439191]
8. Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional characterization of a vascular
addressin involved in lymphocyte homing into peripheral lymph nodes. J. Cell Biol. 1988;
107:1853–1862. [PubMed: 2460470]
9. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J.
1997; 14:585–591. [PubMed: 9298691]
10. Kim YJ, Borsig L, Han HL, Varki NM, Varki A. Distinct selectin ligands on colon carcinoma
mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am.
J. Pathol. 1999; 155:461–472. [PubMed: 10433939]
11. Mitoma J, Bao X, Petryanik B, Schaerli P, Gauguet JM, Yu SY, Kawashima H, Saito H, Ohtsubo
K, Marth JD, Khoo KH, von Andrian UH, Lowe JB, Fukuda M. Critical functions of N-glycans in
L-selectin-mediated lymphocyte homing and recruitment. Nat. Immunol. 2007; 8:409–418.
[PubMed: 17334369]
12. Ohyama C, Tsuboi S, Fukuda M. Dual roles of sialyl lewis X oligosaccharides in tumor metastasis
and rejection by natural killer cells. EMBO J. 1999; 18:1516–1525. [PubMed: 10075923]
13. Martensson S, Bigler SA, Brown M, Lange PH, Brawer MK, Hakomori S. Sialyl-lewis(x) and
related carbohydrate antigens in the prostate. Hum. Pathol. 1995; 26:735–739. [PubMed: 7628844]
14. Wei J, Cui L, Liu F, Fan Y, Lang R, Gu F, Guo X, Tang P, Fu L. E-selectin and sialyl lewis X
expression is associated with lymph node metastasis of invasive micropapillary carcinoma of the
breast. Int. J. Surg. Pathol. 2010; 18:193–200. [PubMed: 18611928]
15. Sumikura S, Ishigami S, Natsugoe S, Miyazono F, Tokuda K, Nakajo A, Okumura H, Matsumoto
M, Hokita S, Aikou T. Disseminated cancer cells in the blood and expression of sialylated antigen
in gastric cancer. Cancer Lett. 2003; 200:77–83. [PubMed: 14550955]
16. Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K. Expression
of sialyl lewis X, sialyl lewis A, E-cadherin and cathepsin-D in human breast cancer:
Immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their
lymph node metastasis. Anticancer Res. 2005; 25:1615–1622. [PubMed: 16033070]
17. Ishibashi Y, Inouye Y, Okano T, Taniguchi A. Regulation of sialyl-lewis x epitope expression by
TNF-alpha and EGF in an airway carcinoma cell line. Glycoconj. J. 2005; 22:53–62. [PubMed:
15864435]

Biochem Biophys Res Commun. Author manuscript; available in PMC 2014 May 06.

Radhakrishnan et al.

Page 8

NIH-PA Author Manuscript
NIH-PA Author Manuscript
NIH-PA Author Manuscript

18. Delmotte P, Degroote S, Lafitte JJ, Lamblin G, Perini JM, Roussel P. Tumor necrosis factor alpha
increases the expression of glycosyltransferases and sulfotransferases responsible for the
biosynthesis of sialylated and/or sulfated lewis x epitopes in the human bronchial mucosa. J. Biol.
Chem. 2002; 277:424–431. [PubMed: 11679593]
19. Kudo T, Ikehara Y, Togayachi A, Morozumi K, Watanabe M, Nakamura M, Nishihara S,
Narimatsu H. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab.
Invest. 1998; 78:797–811. [PubMed: 9690558]
20. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with
clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer.
2004; 90:2312–2316. [PubMed: 15150588]
21. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of
androgen-independent human prostate cancer LNCaP cell model. Prostate. 2002; 50:222–235.
[PubMed: 11870800]
22. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ,
Anderson JR, Lin FF. Decreased expression of cellular prostatic acid phosphatase increases
tumorigenicity of human prostate cancer cells. J. Urol. 2001; 166:1943–1950. [PubMed:
11586265]
23. Radhakrishnan P, Lin MF, Cheng PW. Elevated expression of L-selectin ligand in lymph nodederived human prostate cancer cells correlates with increased tumorigenicity. Glycoconj. J. 2009;
26:75–81. [PubMed: 18670876]
24. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in
facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers
of metastasis. Proc. Natl. Acad. Sci. U. S. A. 2002; 99:2193–2198. [PubMed: 11854515]
25. Mitsuoka C, Sawada-Kasugai M, Ando-Furui K, Izawa M, Nakanishi H, Nakamura S, Ishida H,
Kiso M, Kannagi R. Identification of a major carbohydrate capping group of the L-selectin ligand
on high endothelial venules in human lymph nodes as 6-sulfo sialyl lewis X. J. Biol. Chem. 1998;
273:11225–11233. [PubMed: 9556613]
26. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of
FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile-X syndrome. Am.
J. Hum. Genet. 2000; 66:6–15. [PubMed: 10631132]
27. Balkwill F, Joffroy C. TNF: A tumor-suppressing factor or a tumor-promoting factor? Future
Oncol. 2010; 6:1833–1836. [PubMed: 21142857]
28. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002;
13:135–141. [PubMed: 11900989]
29. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004; 118:671–674. [PubMed:
15369667]
30. Varki A. Selectin ligands. Proc. Natl. Acad. Sci. U. S. A. 1994; 91:7390–7397. [PubMed:
7519775]
31. Cheng, P-W.; Radhakrishnan, P. Mucin glycan branching enzymes: structure, function and gene
regulation. In: Albert, Wu, editor. Molecular Immunology of Complex Carbohydrates-3. Vol. 705.
N.Y.: Plenum Press, N.Y.; 2011. p. 465-492.Advances in Experimental Medicine and Biology
32. Kawashima H, Petryniak B, Hiraoka N, Mitoma J, Huckabyet V, Nakayama J, Uchimura K,
Kadomatsu K, Lowe JB, Fukuda M. N-acetylglucosamine-6-O-sulfotransferases 1 and 2
cooperatively control lymphocyte homing through L-selectin ligand biosynthesis in high
endothelial venues. Nature Immunology. 2005; 6:1096–1104. [PubMed: 16227985]
33. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and
functions. EMBO Rep. 2006; 7:599–604. [PubMed: 16741504]
34. Delcommenne M, Kannagi R, Johnson P. TNF-alpha increases the carbohydrate sulfation of
CD44: Induction of 6-sulfo N-acetyl lactosamine on N- and O-linked glycans. Glycobiology.
2002; 12:613–622. [PubMed: 12244074]
35. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell
invasion and migration in vitro: The role of proteolytic enzymes. Br. J. Cancer. 2003; 89:1123–
1129. [PubMed: 12966436]

Biochem Biophys Res Commun. Author manuscript; available in PMC 2014 May 06.

Radhakrishnan et al.

Page 9

Highlights

NIH-PA Author Manuscript

In this communication, we have made the following observations.
> TNFͣ, a proinflammatory cytokine, enhances the motility and invasiveness of
prostate cancer cells.
> TNFͣ enhances the production of selectin ligands in prostate cancer cells, which
results in increased binding to P-, E-, and L-selectins.
> TNFͣ upregulates the expression of selective glycosyl- and sulfotransferase genes
involved in the synthesis of selectin ligands.
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Fig. 1.

Interactions of selectins and ligands on LNCaP C-81 cells. The decreasing binding order of selectins with C-81 cells were P > L
> E. Treatment of C-81 cells with TNFͣ(20 ng/ml, 36 h) significantly increased the binding of E-selectin (A), P-selectin (B)
and L-selectin (C) when compared with control cells (*, p<0.05; **, p<0.001).
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TNFͣ enhancement of sLex and 6-sulfo-sLex expression on LNCaP C-81 cells. Treatment of LNCaP cells with TNFͣ
(20ng/ml, 36 h) significantly increased higher binding of these cells to anti-sLex (A) and 6-sulfo-sLex (B) antibodies (*, p<0.05;
**, p<0.001).
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Fig. 3.
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Quantitative RT-PCR analysis of glycosyl- and sulfotransferase gene expression. Quantitative real time PCR analysis was
carried out on LNCaP cells with and without TNFͣ treatment (20 ng/ml, 3h). Relative expression level of each gene was sorted
according to Ct (see Materials and Methods) calibrated with GAPDH and expressed as % of GAPDH at basal levels and fold
changes determined by calculating the ratio of the expression level of each gene in TNFͣ treated vs. vehicle-treated cells.
Relative amount of each gene versus that of GAPDH (100%) in untreated control cells was given in the parenthesis (n=3).
Statistical analysis of the difference in means between treated and control cells for each gene was performed by the Student’s ttest (*, p<0.05; **, p<0.01).
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Migration and Invasion of LNCaP cells. LNCaP C-81 cells of 5×104 cells/ml in serum free medium was inoculated in the upper
chambers of 24 well migration and matrigel invasion chamber plates. After 24 h, the cells that transverse to bottom side of the
chamber plates were fixed, stained, and then counted under a phase contrast microscope (40×) in three independent fields for
each insert. The TNFͣ-treated C-81 cells showed a significantly higher level of migration (A, C) and invasion (B, C) than
control cells through polyethylene terapthalate membrane and matrigel invasion chambers, respectively. Pre-incubation of
TNFͣ treated cells with sLex specific antibody (KM93) or E-selectin, significantly reduced the number of cells that migrated
(A, C) and invaded (B, C) when compared with cells treated with TNFͣ alone. The data represented an average of three
independent experiments (*, p<0.001).
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Oligonucleotide primers used for quantitative real-time PCR analysis of different glycosyl- and
sulfotransferases
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Genes

Forward primer sequences 5ᓉ-3ᓉ

Reverse primer sequences 5ᓉ-3ᓉ

Core 1

AGAAGCAAAGGTCACCAGTCCCAA

AGCCAGGATTTAGAGGCCATTTCC

B3GnT3

ATAAGGGAGTGCCAGGGAAGGTTT

ACAGTTGGAACTCTAGCACAGGCA

C2GnT1

GCATGGTTTCTGCAGAGCACAGTT

TTTCCACAATGCCTTGCTACCTGC

C2GnT2

AGAAGCGAGAGCCTTTCACAGACA

TACACAGCTCGCAGTAGCCTTTCA

C2GnT3

GTTCCCTGGGCTTTCCTTGTTTGA

ACTCACCTAAGGCCAAAGGGAACA

B4GalT1

CTAGCAACTTGACCTCGGT

CATTTGGGTTCTGCTTTGCC

B4GalT2

GCATAACGAACCTAACCCTCAG

GCCCAATGTCCACTGTGATA

B4GalT3

GTAACCTCAGTCACCTGCC

ATTCCGCTCCACAATCTCTG

B4GalT4

ACTTCGTGGGTGCCATTCAAGAGA

AAGGAGACACAGAAGGGCAGTTGT

B4GalT5

TGGAACAGAGTACAGAATGCAG

CCTTGCCGTTCTTTTGACTTC

B4GalT6

CTTCACATACTCACCATACCTCC

CCCCTGGCTCAATATCTAAATCC

GlcNAc6ST1

CGAAATGGAGCAGTTTGCCCTGAA

ACTCCTCCACCTGTTTGATCTGCT

GlcNAc6ST2

ATCCCATGAATTTGCTGGGCTACC

AGATGTAGGCAAGGCTCAGAAGCA

GlcNAc6ST3

GCAGACACGCCAAGCTTTGAGAAA

AGCTGCAACGCTGATCACAAATCC

GlcNAc6ST4

TAGTGCAACTTCCTGTGAGCCAGT

TCCATCAAGCCTCACCTCACAACA

ST3GAL3

TGTTCCTGGATGACTCCTTTCGCA

CTTGTTGGCAAGAACGCCTCCATT

ST3GAL4

ATGAGCAGATCACGCTCAAGTCCA

TCCCATCTCCAGCATCCGCTTAAT

ST3GAL5

GCACGGATTAGAACTGGG

CGCCCTCTGGATAAGTCAT

ST3GAL6

TCTATTGGGTGGCACCTGTGGAAA

TGATGAAACCTCAGCAGAGAGGCA

FUT3

AGAGAGATCATCACGGCACGGTTT

ATAAGTGGTGGTCCTGGGCTTGAA

FUT4

TGCAGGTGGGACTTTGTTGTTTGG

TCCTCCAAGGACAATCCAGCACTT

FUT5

TGCCACACTGAATGTCACCTGCTA

TGCTGATGGTCACACACATACCCT

FUT6

ATCACCGCACCGTTTCCAGATGTA

TCCCAAAGTGCTGGGATTACAGGT

FUT7

TTCGTGCATGTGGATGACTTTGGC

AGCGTTGGTATCGGCTCTCATTCA

FUT9

TCCCATGCAGTTCTGATCCAT

CAGCCTCAAGATCATCAGCA

GAPDH

TCGACAGTCAGCCGCATCTTCTTT

ACCAAATCCGTTGACTCCGACCTT
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